Outset Medical, Inc. (OM)
| Market Cap | 79.11M |
| Revenue (ttm) | 119.48M |
| Net Income (ttm) | -81.65M |
| Shares Out | 18.31M |
| EPS (ttm) | -5.37 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 90,915 |
| Open | 4.350 |
| Previous Close | 4.410 |
| Day's Range | 4.290 - 4.350 |
| 52-Week Range | 3.000 - 21.980 |
| Beta | 1.96 |
| Analysts | Strong Buy |
| Price Target | 13.33 (+208.57%) |
| Earnings Date | May 7, 2026 |
About OM
Outset Medical, Inc., a medical technology company, engages in the development of a hemodialysis system for hemodialysis in the United States. The company provides Tablo Hemodialysis System, a compact console with integrated water purification, on-demand dialysate production, and software and connectivity capabilities; and manufactures, supports, and distributes for Tablo console, Tablo cartridge, and other consumables. It also offers Tablo Data Ecosystem, including TabloHub, a consumer-facing portal; MyTablo, a patient-facing portal; and Tablo... [Read more]
Financial Performance
In 2025, Outset Medical's revenue was $119.48 million, an increase of 5.09% compared to the previous year's $113.69 million. Losses were -$81.65 million, -36.20% less than in 2024.
Financial StatementsAnalyst Forecast
According to 3 analysts, the average rating for OM stock is "Strong Buy." The 12-month stock price target is $13.33, which is an increase of 208.57% from the latest price.
News
Outset Medical to Report First Quarter 2026 Financial Results on Thursday, May 7, 2026
SAN JOSE, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to improve clinical outcomes i...
Did Outset Medical, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
Shareholders are urged to contact the firm immediately at no cost or obligation, as there may be limited time to enforce your rights. We would handle the matter on a contingent fee basis, whereby you ...
Outset Medical Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
SAN JOSE, Calif., April 08, 2026 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (Nasdaq: OM), a medical technology company pioneering a first of-its-kind technology to improve clinical outcomes in dialysis ...
Outset Medical Names Derick Elliott as Executive Vice President of Commercial
SAN JOSE, Calif., April 06, 2026 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (Nasdaq: OM), a medical technology company pioneering a first-of-its-kind technology to improve clinical outcomes in dialysis ...
Outset Medical Earnings Call Transcript: Q4 2025
Revenue grew 5% in 2025 to $119.5M, with gross margin expansion and reduced cash burn. FDA clearance of the next-gen Tablo platform positions the company for further growth, with 2026 revenue guidance of $125M–$130M and continued margin improvement.
Outset Medical Reports Fourth Quarter and Full Year 2025 Financial Results
SAN JOSE, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (Nasdaq: OM), a medical technology company pioneering a first-of-its-kind technology to improve clinical outcomes in dialysis with less...
Next-Generation Tablo Hemodialysis System Receives FDA Clearance, Second Quarter Launch Planned
SAN JOSE, Calif., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (Nasdaq: OM), a medical technology company pioneering a first-of-its-kind technology to improve clinical outcomes in dialysis w...
Outset Medical to Report Fourth Quarter 2025 Financial Results on Wednesday, February 11, 2026
SAN JOSE, Calif., Jan. 26, 2026 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexi...
Outset Medical Transcript: 44th Annual J.P. Morgan Healthcare Conference
Operating at scale in acute and home dialysis markets, the company leverages innovative technology and a recurring revenue model to drive growth and improve patient outcomes. Strong financials, high retention rates, and a focus on gross margin expansion position it for continued market share gains and profitability.
Outset Medical Reports Unaudited Fourth Quarter and 2025 Results
SAN JOSE, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (Nasdaq: OM), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, tod...
Outset Medical to Present at the 44th Annual J.P. Morgan Healthcare Conference
SAN JOSE, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexi...
Outset Medical Transcript: Stifel 2025 Healthcare Conference
The organization has made significant operational and sales model improvements, resolving regulatory issues and enhancing recurring revenue streams. Q3 results missed expectations due to deal timing, but recurring revenue remains strong and margin improvement is on track. Leadership is confident in future growth and profitability.
Outset Medical, Gemini Space Station, CoreWeave And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
U.S. stock futures were mostly lower this morning, with the S&P 500 futures falling around 0.2% on Tuesday.
Outset Medical Earnings Call Transcript: Q3 2025
Q3 revenue grew 3% year-over-year to $29.4M, but large enterprise deals shifted to Q4/2026, prompting a guidance cut to $115–$120M for 2025. Gross margin reached 39.9%, and cash use is projected to drop over 50% in 2025. Demand and pipeline remain strong.
Outset Medical Reports Third-Quarter Results
SAN JOSE, Calif., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (Nasdaq: OM), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialy...
New Research Demonstrates the Advantages of an Insourced Dialysis Service Line for Acute-Care Facilities Using Outset Medical's Tablo® Hemodialysis System
Data from over 1 Million Tablo Treatments Among the Findings Presented at the American Society of Nephrology's Kidney Week 2025 Data from over 1 Million Tablo Treatments Among the Findings Presented a...
Outset Medical to Present at the 2025 Stifel Healthcare Conference
SAN JOSE, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexi...
Outset Medical to Report Third Quarter 2025 Financial Results on Monday, November 10, 2025
SAN JOSE, Calif., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexi...
Outset Medical Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference
Strong year-over-year growth is driven by a differentiated technology and a recurring revenue model, with significant progress in gross margin and operational efficiency. Acute and post-acute market penetration is accelerating, supported by a unique value proposition and robust sales transformation. Recurring revenue and acute care market strength are highlighted as underappreciated advantages.
Northwest Kidney Centers and Outset Medical Announce Collaboration to Grow Home Hemodialysis
Collaboration to provide patients and caregivers access to innovative home dialysis with the Tablo® Hemodialysis System Collaboration to provide patients and caregivers access to innovative home dialy...
Outset Medical to Present at the 23rd Annual Morgan Stanley Global Healthcare Conference
SAN JOSE, Calif., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexi...
Top 3 Health Care Stocks That Are Preparing To Pump This Month
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
Outset Medical Earnings Call Transcript: Q2 2025
Second quarter revenue grew 15% year-over-year to $31.4 million, driven by strong console sales and recurring revenue. Gross margin expanded to 38.4%, and full-year guidance was raised to $122–$126 million, reflecting confidence in commercial execution and market demand.
Outset Medical Second-Quarter Results Demonstrate Continued Momentum, Punctuated by Strong Revenue Growth, Console Placements and Utilization
Company raises 2025 revenue guidance to a range of $122 million to $126 million Company raises 2025 revenue guidance to a range of $122 million to $126 million
Outset Medical Names First Chief Nursing Officer
SAN JOSE, Calif., July 30, 2025 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexi...